Gender-Related Approach to Kidney Cancer Management: Moving Forward

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2020 May 14

PMID 32397685

Citations 26

Authors

Mariangela Mancini

Marialaura Righetto

Giovannella Baggio

Affiliations

Soon will be listed here.

Abstract

Men are more frequently diagnosed with kidney cancer than women, with a more aggressive histology, larger tumors, a higher grade and stage, and worse oncological outcomes. Smoking habits and sex steroid hormones seem to have a possible role in explaining these gender disparities. Moreover, the expression of genes involved in tumor growth and immune response in kidney cancer varies between men and women, having an impact on the gender-related response to oncological therapy, such as anti-angiogenic drugs and immunotherapy. Recent advances have been made in our understanding of the molecular and genetic mechanisms involved in kidney cancer, which could partially explain the gender differences, and they are summarized in this paper. However, other key mechanisms, which fully clarify the striking clinical gender-related differences observed in kidney cancer, are not completely understood at present. We reviewed and summarized the most relevant publications about the relationship between gender and kidney cancer. Efforts should be made to progress in bench and clinical research on gender-related signatures and disparities, and their impact on the clinical management of kidney cancer.

Citing Articles

The correlation between serum sex hormone levels and clear cell renal cell carcinoma in male patients.

Yu Z, Zhao C, Yang A, Liu X, Xia Y, Cui R Sci Rep. 2025; 15(1):7256.

PMID: 40025134 PMC: 11873295. DOI: 10.1038/s41598-025-90983-4.

Nrf2 Signaling in Renal Cell Carcinoma: A Potential Candidate for the Development of Novel Therapeutic Strategies.

Schiavoni V, Emanuelli M, Milanese G, Galosi A, Pompei V, Salvolini E Int J Mol Sci. 2025; 25(24.

PMID: 39769005 PMC: 11675435. DOI: 10.3390/ijms252413239.

Prognostic value of B7-H3 expression in metastatic renal cell carcinoma and its impact on immunotherapy response.

Ozalp F, Yorukoglu K, Caliskan Yildirim E, Uzun M, Semiz H BMC Cancer. 2024; 24(1):1471.

PMID: 39614178 PMC: 11606205. DOI: 10.1186/s12885-024-13238-x.

In Vivo and In Vitro Response to a Regenerative Dental Scaffold.

Gould M, Deng X, Lyons K, Ali A Materials (Basel). 2024; 17(21).

PMID: 39517658 PMC: 11547789. DOI: 10.3390/ma17215384.

Ochratoxin A and Its Role in Cancer Development: A Comprehensive Review.

Wieckowska M, Cichon N, Szelenberger R, Gorniak L, Bijak M Cancers (Basel). 2024; 16(20).

PMID: 39456567 PMC: 11506779. DOI: 10.3390/cancers16203473.

References

Lipworth L, Morgans A, Edwards T, Barocas D, Chang S, Herrell S . Renal cell cancer histological subtype distribution differs by race and sex. BJU Int. 2014; 117(2):260-5. DOI: 10.1111/bju.12950. View

Rosiello G, Knipper S, Palumbo C, Dzyuba-Negrean C, Pecoraro A, Mazzone E . Unmarried status is a barrier for access to treatment in patients with metastatic renal cell carcinoma. Int Urol Nephrol. 2019; 51(12):2181-2188. DOI: 10.1007/s11255-019-02266-3. View

Dy G, Gore J, Forouzanfar M, Naghavi M, Fitzmaurice C . Global Burden of Urologic Cancers, 1990-2013. Eur Urol. 2016; 71(3):437-446. DOI: 10.1016/j.eururo.2016.10.008. View

Ito H, Makiyama K, Kawahara T, Osaka K, Izumi K, Yokomizo Y . The impact of gender difference on operative time in laparoscopic partial nephrectomy for T1 renal tumor and the utility of retroperitoneal fat thickness as a predictor of operative time. BMC Cancer. 2016; 16(1):944. PMC: 5154121. DOI: 10.1186/s12885-016-2979-5. View

Motzer R, Escudier B, Mcdermott D, George S, Hammers H, Srinivas S . Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1803-13. PMC: 5719487. DOI: 10.1056/NEJMoa1510665. View

Zhu G, Liang L, Li L, Dang Q, Song W, Yeh S . The expression and evaluation of androgen receptor in human renal cell carcinoma. Urology. 2013; 83(2):510.e19-24. DOI: 10.1016/j.urology.2013.10.022. View

Bauman T, Potretzke A, Wright A, Knight B, Vetter J, Figenshau R . Partial Nephrectomy for Presumed Renal-Cell Carcinoma: Incidence, Predictors, and Perioperative Outcomes of Benign Lesions. J Endourol. 2017; 31(4):412-417. DOI: 10.1089/end.2016.0667. View

Kim J, Li S, Khandwala Y, Chung K, Park H, Chung B . Association of Prevalence of Benign Pathologic Findings After Partial Nephrectomy With Preoperative Imaging Patterns in the United States From 2007 to 2014. JAMA Surg. 2018; 154(3):225-231. PMC: 6439638. DOI: 10.1001/jamasurg.2018.4602. View

Mancini M, Righetto M, Baggio G . Spotlight on gender-specific disparities in bladder cancer. Urologia. 2019; 87(3):103-114. DOI: 10.1177/0391560319887327. View

10.

Hew M, Zonneveld R, Kummerlin I, Opondo D, de la Rosette J, Laguna M . Age and gender related differences in renal cell carcinoma in a European cohort. J Urol. 2012; 188(1):33-8. DOI: 10.1016/j.juro.2012.02.2573. View

11.

Brannon A, Haake S, Hacker K, Pruthi R, Wallen E, Nielsen M . Meta-analysis of clear cell renal cell carcinoma gene expression defines a variant subgroup and identifies gender influences on tumor biology. Eur Urol. 2011; 61(2):258-68. PMC: 3244546. DOI: 10.1016/j.eururo.2011.10.007. View

12.

Mauermann J, de Martino M, Waldert M, Haitel A, Klingler H, Remzi M . Gender differences in benign renal masses. World J Urol. 2013; 31(5):1051-7. DOI: 10.1007/s00345-013-1032-4. View

13.

Minnillo B, Horowitz A, Finelli A, Alibhai S, Ponsky L, Abouassaly R . Does gender influence morbidity or mortality in the surgical treatment of renal masses?. Can Urol Assoc J. 2014; 8(5-6):E311-6. PMC: 4039593. DOI: 10.5489/cuaj.1674. View

14.

Marchioni M, Martel T, Bandini M, Pompe R, Tian Z, Kapoor A . Marital status and gender affect stage, tumor grade, treatment type and cancer specific mortality in T N M renal cell carcinoma. World J Urol. 2017; 35(12):1899-1905. DOI: 10.1007/s00345-017-2082-9. View

15.

May M, Aziz A, Zigeuner R, Chromecki T, Cindolo L, Schips L . Gender differences in clinicopathological features and survival in surgically treated patients with renal cell carcinoma: an analysis of the multicenter CORONA database. World J Urol. 2013; 31(5):1073-80. DOI: 10.1007/s00345-013-1071-x. View

16.

Noh S, Kang M, Kim K, Bae J, Park H, Moon W . Acetylation status of P53 and the expression of DBC1, SIRT1, and androgen receptor are associated with survival in clear cell renal cell carcinoma patients. Pathology. 2013; 45(6):574-80. DOI: 10.1097/PAT.0b013e3283652c7a. View

17.

Chen Y, Sun Y, Rao Q, Xu H, Li L, Chang C . Androgen receptor (AR) suppresses miRNA-145 to promote renal cell carcinoma (RCC) progression independent of VHL status. Oncotarget. 2015; 6(31):31203-15. PMC: 4741598. DOI: 10.18632/oncotarget.4522. View

18.

Bertrand L, Thomas L, Li P, Buchta C, Boi S, Orlandella R . Obesity as defined by waist circumference but not body mass index is associated with higher renal mass complexity. Urol Oncol. 2017; 35(11):661.e1-661.e6. PMC: 5660914. DOI: 10.1016/j.urolonc.2017.06.058. View

19.

Liu H, Wang X, Hu G, Huang T, Xu Y . Oral contraceptive use and kidney cancer risk among women: evidence from a meta-analysis. Int J Clin Exp Med. 2015; 7(11):3954-63. PMC: 4276161. View

20.

OMalley R, Underwood 3rd W, Brewer K, Hayn M, Kim H, Mehedint D . Gender disparity in kidney cancer treatment: women are more likely to undergo radical excision of a localized renal mass. Urology. 2013; 82(5):1065-9. DOI: 10.1016/j.urology.2013.06.060. View